RAPGEF4

Across TCGA pan-cancer cohorts, RAPGEF4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAPGEF4 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAPGEF4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAPGEF4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where RAPGEF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.815	0.352	<.001	48	view →
HNSC	DFS	Median	II,III,IV	0.938	0.615	.009	17	view →
GBM	DFS	Tertile	All	0.919	0.625	<.001	12	view →
PDAC	DFS	Tertile	II,III,IV	1.000	0.397	.024	9	view →
LUAD	OS	Tertile	III,IV	0.778	1.000	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAPGEF4–CCRCC (DFS)

Open the CCRCC breakdown →